Beta Bionics (BBNX) CFO Stephen Feider Exercises Options and Sells Shares

What Happened
Stephen Feider, Chief Financial Officer of Beta Bionics (BBNX), exercised stock options to acquire a total of 10,000 shares (5,104 on 2026‑06‑26 and 4,896 on 2026‑06‑29) at an exercise price of $5.10 per share (cost ≈ $51,000). He then sold those same 10,000 shares in open‑market transactions under a Rule 10b5‑1 plan for total gross proceeds of about $170,387 (sales: 5,104 shares at an average ≈ $17.0468 on 6/26 for $87,006; 4,896 shares at an average ≈ $17.0304 on 6/29 for $83,381). This filing is an amendment to correct the number of shares and post‑transaction holdings.

Key Details

• Transaction dates and prices:
  • 2026‑06‑26: Exercised 5,104 options @ $5.10 (acquired) and sold 5,104 shares at weighted avg $17.0468 (range $17.00–$17.12).
  • 2026‑06‑29: Exercised 4,896 options @ $5.10 (acquired) and sold 4,896 shares at weighted avg $17.0304 (range $17.00–$17.08).
• Proceeds/costs: Sale proceeds ≈ $170,387; exercise cost ≈ $51,000.
• Shares owned after transaction: Not specified in the excerpt of this filing provided here.
• Notable footnotes:
  • Sales were made pursuant to a Rule 10b5‑1 trading plan adopted May 15, 2025 (F2).
  • The Form 4 was amended to correct the number of shares subject to the June 26 exercise and the post‑transaction beneficial ownership (F1).
  • Weighted average sale prices and price ranges are listed; the filing notes full price breakdowns are available on request (F3, F4).
  • The options vest monthly over 48 months beginning Sept 14, 2023 (F5).
• Derivative entries showing $0.00 disposed: these reflect termination/cancellation of option instruments upon exercise (reported as derivative disposition).

Context
This was an option exercise immediately followed by an open‑market sale of the acquired shares — a common pattern when insiders exercise options and use prearranged 10b5‑1 plans to sell shares. Such sales typically represent liquidity events rather than a direct signal about company prospects. The filing is amended to correct previously reported numbers; consult the full amended Form 4 for the post‑transaction beneficial ownership details.